RxDoctor Payments Data

Mihail Paxos, MD

Interventional Cardiology · Cleveland, OHNPI 1902040173

Payments from drug & device makers

$10,735in general payments, 2019–2025

Across 174 payments — averaging $61.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Edwards Lifesciences$2K
  • Boston Scientific$2K
  • Medtronic$1K
  • Abiomed$365
  • Terumo Medical Corporation$312
  • plus $939 from 13 others

What the payments were for

  • Travel & lodging$4,60743%
  • Food & beverage$6,12757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,735 in reported general payments places this provider in the 60th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$158,736
Medicare patients
469
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$66,542
EntrestoSacubitril/Valsartan71$66,230
JardianceEmpagliflozin48$36,587
Repatha SureclickEvolocumab30$31,382
XareltoRivaroxaban23$14,639
Metoprolol Succinate355$3,918
ClopidogrelClopidogrel Bisulfate217$2,833
Ezetimibe125$1,893
Atorvastatin Calcium163$1,403
Rosuvastatin Calcium117$940
Losartan Potassium164$756
Bumetanide17$704
Amlodipine Besylate148$673
Prasugrel Hcl19$620
SotalolSotalol Hcl19$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$66,54276 claims
NovartisEntresto$24$66,23071 claims
Johnson & JohnsonXarelto$176$14,63923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →